309 related articles for article (PubMed ID: 11061580)
1. In vivo modulation of CYP enzymes by quinidine and rifampin.
Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
3. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
Damkier P; Hansen LL; Brosen K
Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487
[TBL] [Abstract][Full Text] [Related]
4. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
5. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
[TBL] [Abstract][Full Text] [Related]
6. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
Damkier P; Brøsen K
Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
[TBL] [Abstract][Full Text] [Related]
7. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
Chen XP; Tan ZR; Huang SL; Huang Z; Ou-Yang DS; Zhou HH
Clin Pharmacol Ther; 2003 Mar; 73(3):264-71. PubMed ID: 12621391
[TBL] [Abstract][Full Text] [Related]
8. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
9. Assessment of cytochrome P450 activity by a five-drug cocktail approach.
Zhu B; Ou-Yang DS; Chen XP; Huang SL; Tan ZR; He N; Zhou HH
Clin Pharmacol Ther; 2001 Nov; 70(5):455-61. PubMed ID: 11719732
[TBL] [Abstract][Full Text] [Related]
10. Effect of fluvoxamine on the pharmacokinetics of quinidine.
Damkier P; Hansen LL; Brøsen K
Eur J Clin Pharmacol; 1999 Aug; 55(6):451-6. PubMed ID: 10492058
[TBL] [Abstract][Full Text] [Related]
11. Human cytochrome P450s: selectivity and measurement in vivo.
Smith DA; Abel SM; Hyland R; Jones BC
Xenobiotica; 1998 Dec; 28(12):1095-128. PubMed ID: 9890156
[No Abstract] [Full Text] [Related]
12. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
[TBL] [Abstract][Full Text] [Related]
13. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.
Caraco Y; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Oct; 60(4):396-404. PubMed ID: 8873687
[TBL] [Abstract][Full Text] [Related]
14. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
16. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Adedoyin A; Arns PA; Richards WO; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1998 Jul; 64(1):8-17. PubMed ID: 9695714
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ
Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
19. Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women.
O'Connell MB; Frye RF; Matzke GR; St Peter JV; Willhite LA; Welch MR; Kowal P; LaValleur J
J Clin Pharmacol; 2006 Nov; 46(11):1299-307. PubMed ID: 17050794
[TBL] [Abstract][Full Text] [Related]
20. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
Johnson JA; Herring VL; Wolfe MS; Relling MV
J Pharmacol Exp Ther; 2000 Sep; 294(3):1099-105. PubMed ID: 10945865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
